Medical Innova Spółka z Ograniczoną Odpowiedzialnością (KRS 0001239096, NIP 8222424236) is a Polish company, headquartered in Brzeziny, Mazowieckie voivodeship. MEDICAL INNOVA operates in: Retail sale of medical and orthopaedic goods in specialised stores (PKD 47.74.Z). Industry: Retail trade. The company has been listed in the National Court Register since April 28, 2026.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Medical Innova
Identity
- Name
- Medical Innova Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- April 28, 2026
- Registry status as of
- April 29, 2026
- Latest entry
- April 29, 2026
- Founding act
- 22.04.2026 R.
Articles of association history (1)
- April 22, 2026: 22.04.2026 R.
Activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. JANA III SOBIESKIEGO, 2, 05-074, BRZEZINY, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- MIŃSKI
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-96314-63255-SJHDW-29
Operational status - Medical Innova
Founded
April 28, 2026
0 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
BRZEZINY
MAZOWIECKIE
Primary PKD
47.74.Z
Retail sale of medical and orthopaedic goods in specialised stores
Share capital
600.0 K PLN
6,000 shares total
Shareholders
2
shareholders
Board
2 people
Filed years
N/A
Registry entries
4
latest: April 29, 2026
No KPI data - financial statements and valuation are unavailable for this company.
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Medical Innova.
No ratings
Related articles
News
Ambra in 2026: PLN 48.1 m capex (+212%), PLN 1.10 dividend three years running, Cydr Lubelski plus Romanian Zarea as the premium engine
Warsaw-based Ambra S.A. (KRS 0000041726, ul. Puławska 336) closed H1 of fiscal 2025/2026 with PLN 556.8 m of revenue and PLN 49.0 m of net profit, while raising capex by 212% to PLN 48.1 m - mainly for the soft-drinks line in Wola Duża and the PLN 11.9 m acquisition of a Romanian company. Despite the aggressive investment cycle the board keeps a PLN 1.10 dividend per share for the third year running (~5.9% yield).
News
Answear in 2026: first full year without MCI, PLN 9.3 m net profit, but the supervisory board cuts the 2026 EBITDA target from PLN 100 m to PLN 90 m
Kraków-based Answear.com S.A. (KRS 0000816066) closed 2025 with revenue of PLN 1.7 bn (+13% YoY), EBITDA of PLN 56 m (+63%) and net profit of PLN 9.3 m - a return to the black after a PLN 10 m loss in 2024. Poland grew +31%, but CEE was under FX pressure (hryvnia -11% vs PLN), and a weak Q4 (EBITDA -71% YoY) forced the supervisory board to cut the 2026 EBITDA target from PLN 100 m to PLN 90 m and the target price from PLN 50 to PLN 45. It is the first full year after MCI's exit from the shareholder base (10 June 2025); the Bajołek brothers retain control (57.8%).
